drugset / Trial / NCT03499899
A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The main purpose of this study was to assess the antitumor activity of three combinations: i) LAG525 + spartalizumab; ii) LAG525 + spartalizumab + carboplatin, and iii) LAG525 + carboplatin in participants with advanced triple-negative breast cancer (TNBC) in first or second line therapy.
Timeline
- Start
- 2018-07-02
- Primary completion
- 2020-02-27
- Completion
- 2021-11-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 6 unknown | Intravenous |
| Subject | Spartalizumab | Monoclonal antibody | 300 mg | Intravenous |
| Subject | ieramilimab | Monoclonal antibody | 400 mg | Intravenous |